Circassia Pharmaceuticals Plc is raising £275 million on the London Stock Exchange following its initial public offering in March 2014 of £202 million. The developer of immunotherapies for allergies will use the proceeds to buy two other companies for an aggregate of up to £239 million.
Juno Therapeutics Inc has acquired Stage Cell Therapeutics GmbH, a privately-owned biotechnology company in Germany, in order gain access to research and manufacturing technologies and to a pipeline of clinical and preclinical assets.
Pfizer Inc has acquired a minority stake in privately-held AM-Pharma BV which has a Phase 2 product for acute kidney injury related to sepsis. The US company made an upfront payment of $87.5 million to AM-Pharma in early May for the stake, and also secured an exclusive option to buy the rest of the company.
Gilead Sciences Inc has acquired privately-held EpiTherapeutics ApS for $65 million in cash. The Denmark-based company has a library of small molecules that inhibit the epigenetic regulation of gene transcription which has uses in combating cancer.
Adaptimmune Therapeutics Plc of the UK has raised $191.3 million in an initial public offering of its shares on Nasdaq. The offer of 11.25 million American Depositary Shares (ADSs) was priced at $17 per share. Approximately 1.7 million shares have also been set aside for overallotments.
MorphoSys AG has acquired Lanthio Pharma BV of the Netherlands, a company with technology that can be used to identify peptides which are selective for a specific disease target and stabilise them for receptor binding.
Kymab Ltd of Cambridge UK has raised an additional $50 million in a Series B financing round bringing the total raised to $90 million. The new funds were provided by Woodford Patient Capital Trust Plc and Malin Corporation Plc, which itself recently raised €330 million in an initial public offering on the Irish Stock Exchange.
GW Pharmaceuticals Plc, a developer of cannabinoid medicines, has raised $179.2 million through a share offering on the Nasdaq exchange, the company’s third follow-on financing following an initial public offering of its shares in the US in May 2013.
Affimed Therapeutics AG of Germany is planning a follow-on financing of $35 million on Nasdaq to support development of its portfolio of bispecific antibodies. In September 2014 the company raised $56 million in an initial public offering of its shares.
Labco, a French diagnostics company with 160 laboratories spread over seven countries, is making an initial public offering on its shares on the Euronext Paris stock exchange and a simultaneous secondary offering.